# The Effect of Liposomal Bupivacaine on Post Operative Pain and Narcotic Use After Bariatric Surgery

> **NCT03196505** · PHASE4 · COMPLETED · sponsor: **University of California, San Francisco** · enrollment: 231 (actual)

## Conditions studied

- Bariatric Surgery Candidate
- Pain, Postoperative

## Interventions

- **DRUG:** Exparel 266 MG Per 20 ML Injection
- **DRUG:** Bupivacaine

## Key facts

- **NCT ID:** NCT03196505
- **Lead sponsor:** University of California, San Francisco
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-12-04
- **Primary completion:** 2019-07-31
- **Final completion:** 2019-07-31
- **Target enrollment:** 231 (ACTUAL)
- **Last updated:** 2020-11-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03196505

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03196505, "The Effect of Liposomal Bupivacaine on Post Operative Pain and Narcotic Use After Bariatric Surgery". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03196505. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*